keyword
https://read.qxmd.com/read/38474476/exploring-novel-antidepressants-targeting-g-protein-coupled-receptors-and-key-membrane-receptors-based-on-molecular-structures
#21
REVIEW
Hanbo Yao, Xiaodong Wang, Jiaxin Chi, Haorong Chen, Yilin Liu, Jiayi Yang, Jiaqi Yu, Yongdui Ruan, Xufu Xiang, Jiang Pi, Jun-Fa Xu
Major Depressive Disorder (MDD) is a complex mental disorder that involves alterations in signal transmission across multiple scales and structural abnormalities. The development of effective antidepressants (ADs) has been hindered by the dominance of monoamine hypothesis, resulting in slow progress. Traditional ADs have undesirable traits like delayed onset of action, limited efficacy, and severe side effects. Recently, two categories of fast-acting antidepressant compounds have surfaced, dissociative anesthetics S-ketamine and its metabolites, as well as psychedelics such as lysergic acid diethylamide (LSD)...
February 22, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38472415/synergistic-use-of-deep-tms-therapy-with-iv-ketamine-infusions-for-major-depressive-disorder-a-pilot-study
#22
JOURNAL ARTICLE
Nathaniel A Shanok, Sabrina Muzac, Leah Brown, Melissa Barrera, Raul Rodriguez
OBJECTIVE: Major Depressive Disorder (MDD) is a pervasive psychiatric condition effecting approximately 21 million adults in the U.S. (8.4%). An estimated 30-60% of patients are resistant to traditional treatment approaches (medications and talk-therapy), alluding to the need for additional options. Two promising treatment modalities include transcranial magnetic stimulation (TMS) and ketamine infusions; both have shown efficacy in standalone studies but have scarcely been investigated synergistically in the same group of participants...
March 12, 2024: Psychopharmacology
https://read.qxmd.com/read/38463814/comparing-sedation-protocols-for-endoscopic-retrograde-cholangiopancreatography-ercp-a-retrospective-study
#23
JOURNAL ARTICLE
Ning Zhang, Guanjun Li
BACKGROUND: Endoscopic retrograde cholangiopancreatography (ERCP) is a widely used diagnostic and therapeutic procedure. Effective sedation is crucial to enhance patient comfort and optimize endoscopist performance. Various sedation protocols, including Propofol and Dexmedetomidine (Pro-Dex), Ketamine and Propofol (Keto-Fol), Propofol and Midazolam (Pro-Mid), and Propofol alone, have been utilized during ERCP. This retrospective study aims to compare the safety and efficacy of these four sedation protocols...
March 15, 2024: Heliyon
https://read.qxmd.com/read/38451731/differential-effects-of-repeated-fluoxetine-and-ketamine-administration-on-behavioral-and-pharmacological-stressor-induced-depression-of-digging-behavior-in-mice
#24
JOURNAL ARTICLE
Kaitlyn J Partridge, Todd M Hillhouse
Major depressive disorder is a multifactorial disorder that originates from a complex web of variables and overlaps with similar disorders (e.g., depression and anxiety). As such, animal models should account for the considerable symptom overlap between psychiatric disorders. We sought to extend the findings of behavioral assays that encompass both anxiety and stress/depression components. To do so, we have focused on digging behavior, a compulsive-like behavior displayed in mice, in which we employed behavioral and pharmacological stressors to reduce digging behaviors, producing a depression-like state...
March 7, 2024: Experimental and Clinical Psychopharmacology
https://read.qxmd.com/read/38451024/antinociceptive-and-adverse-effects-of-morphine-ketamine-mixtures-in-rats
#25
JOURNAL ARTICLE
Conor D Strumberger, Evangeline J D'Epagnier, Kevin H Nguyen, John D Rogers, Matthew P Meyer, Yashmita Malhotra, Jillian E Hinman, Elisabeth L Jansen, Vanessa Minervini
Prescription opioids are the gold standard for treating moderate to severe pain despite their well-documented adverse effects. Of all prescription medications, opioids are abused most widely, and fatal overdoses have reached epidemic levels. One strategy for improving the margin of safety of opioids is combining them with non-opioid drugs to decrease the opioid dose needed for pain relief, thereby reducing adverse effects that occur with larger doses. The N-methyl-D-aspartate receptor antagonist ketamine has been used safely as an analgesic but only under a very limited range of conditions...
April 1, 2024: Behavioural Pharmacology
https://read.qxmd.com/read/38449472/a-phase-2-open-label-study-of-efficacy-safety-and-tolerability-of-sls-002-intranasal-racemic-ketamine-in-adults-with-mdd-at-imminent-risk-of-suicide
#26
JOURNAL ARTICLE
Timothy Whitaker, Kimberly F Farrand, Michael E Thase
BACKGROUND: Despite the prevalence of Major Depressive Disorder (MDD) and the propensity of affected individuals to eventually die by suicide, there is no therapeutic approved specifically for suicidal ideation and behavior (SI/B) in MDD. The NMDA receptor antagonist ketamine has been investigated for the treatment of depression and shown to have a rapid effect on symptoms. Spravato® (esketamine) is approved by the FDA for use in treatment-resistant depression and Major Depressive Episodes with Suicidal Ideation based on studies conducted in adults also taking standard antidepressants...
March 4, 2024: Psychopharmacology Bulletin
https://read.qxmd.com/read/38445088/case-report-adult-with-bipolar-disorder-and-autism-treated-with-ketamine-assisted-psychotherapy
#27
Christopher P Harris, Becky Jones, Kathryn Walker, Meredith S Berry
BACKGROUND: Evidence has increased in recent years regarding the potential for ketamine to serve as a novel treatment option for a range of conditions, particularly depression (unipolar and bipolar). However, research regarding ketamine as a potential therapeutic for Autism Spectrum Disorder (ASD) is lacking, despite high overlap with bipolar depression and theoretical foundations for its use. CASE PRESENTATION: A 29-year-old man with bipolar disorder and Autism Spectrum Disorder, type 2 diabetes, presented with mood swings and suicidal thoughts, and anger outbursts occurring daily...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38444407/ketamine-for-depressive-symptoms-a-retrospective-chart-review-of-a-private-ketamine-clinic
#28
JOURNAL ARTICLE
Vidette M Juby, Saaeda Paruk, Mitsuaki Tomita, Bonga Chiliza
BACKGROUND: There is currently no published evidence demonstrating the effectiveness and safety of subanaesthetic doses of ketamine, when administered intravenously as an adjunct treatment for depressive symptoms, in a real world setting in South Africa. AIM: This retrospective chart review reports the clinical response (change in Patient Health Questionnaire - 7 score) to an initial infusion series of ketamine added to usual treatment, and the pattern of its subsequent maintenance use, for depressive symptoms...
2024: South African Journal of Psychiatry: SAJP
https://read.qxmd.com/read/38440104/patient-reported-outcomes-on-sleep-quality-and-circadian-rhythm-during-treatment-with-intravenous-ketamine-for-treatment-resistant-depression
#29
JOURNAL ARTICLE
Raymond Yan, Tyler Marshall, Atul Khullar, Travis Nagle, Jake Knowles, Mai Malkin, Brittany Chubbs, Jennifer Swainson
BACKGROUND: Intravenous (IV) ketamine is a rapid acting antidepressant used primarily for treatment-resistant depression (TRD). It has been suggested that IV ketamine's rapid antidepressant effects may be partially mediated via improved sleep and changes to the circadian rhythm. OBJECTIVES: This study explores IV ketamine's association with changes in patient-reported sleep quality and circadian rhythm in an adult population with TRD. METHODS: Adult patients (18-64 years) with TRD scheduled for IV ketamine treatment were recruited to complete patient rated outcomes measures on sleep quality using the Pittsburgh Sleep Quality Index (PSQI) and circadian rhythm using the Morningness-Eveningness Questionnaire (MEQ)...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38439794/anhedonia-and-depression-severity-measures-during-ketamine-administration-in-treatment-resistant-depression
#30
JOURNAL ARTICLE
Aleksander Kwaśny, Wiesław Jerzy Cubała, Adam Włodarczyk
BACKGROUND: Anhedonia is a core symptom of depression characterized by a diminished ability to experience pleasure. Currently available treatments for depression often fall short in adequately addressing anhedonia that often presents as a chronic and debilitating symptom. Ketamine is known to possess antianhedonic properties. METHODS: This post-hoc analysis of a naturalistic observational study of treatment-resistant depression inpatients (n=28) analyzed antianhedonic response patterns measured by Snaith-Hamilton Pleasure Scale and changes in Inventory of Depressive Symptomatology in responders (n=6) and non-responders (n=22) stratified per Montgomery-Åsberg Depression Rating Scale during short-term ketamine treatment...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38435232/ketamine-in-chronic-pain-a-review
#31
REVIEW
Ana Faísco, Rita Dinis, Tânia Seixas, Luís Lopes
Ketamine has been used in the treatment of several pain syndromes, particularly those with a relevant neuropathic component. Sub-anesthetic doses of ketamine produce a potent analgesic effect, due to its inhibition of N-methyl-D-aspartate receptors and enhancement of descending inhibitory pathways. Its short-term analgesic effect is well-documented perioperatively, with an associated reduction in postoperative chronic pain and opioid consumption. Despite some evidence regarding its long-term benefits, the number of clinical studies is still limited...
February 2024: Curēus
https://read.qxmd.com/read/38428531/efficacy-of-perioperatively-application-of-ketamine-on-postoperative-depressive-symptoms-in-adult-patients-a-systematic-review-and-meta-analysis-with-trial-sequential-analysis
#32
REVIEW
Qingfeng Wei, Mengmeng Li, Yu Jiang, Xuesheng Liu
BACKGROUND: Whether ketamine used in the perioperative period reduces the risk of postoperative depressive symptoms remains uncertain. We conducted this systematic review and meta-analysis to evaluate the clinical efficacy of ketamine in adult surgical patients. METHODS: Two investigators independently systematically searched the Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Web of Science, and PsycINFO databases using a combination of relevant Medical Subject Headings terms and free-text keywords from database inception through May 24, 2023...
February 28, 2024: Journal of Affective Disorders
https://read.qxmd.com/read/38424390/association-of-chronic-poststernotomy-pain-and-health-related-quality-of-life-a-prospective-cohort-study
#33
JOURNAL ARTICLE
Terri Sun, Mikayla Fan, Defen Peng, Lauren Li, Alyson Ree, Alana M Flexman, Ainsley M Sutherland, Stephan K W Schwarz, Tim Ting Han Jen, Cynthia H Yarnold
PURPOSE: Chronic poststernotomy pain (CPSP) after cardiac surgery is multifactorial and impacts patient recovery. We aimed to evaluate the association between CPSP severity and health-related quality of life at six months after cardiac surgery. METHODS: This was a single-centre prospective cohort study of patients who underwent cardiac surgery with median sternotomy between September 2020 and March 2021. Telephone interviews were conducted at six and 12 months postoperatively using the Short Form McGill Pain Questionnaire and the EQ-5D-5L...
February 29, 2024: Canadian Journal of Anaesthesia
https://read.qxmd.com/read/38421927/rapid-improvement-of-post-partum-depression-with-subanesthetic-racemic-ketamine
#34
JOURNAL ARTICLE
Émilie Guay, Marie-Josée Brouillette, Jessica Drury, Nicolas Garel, Kyle Greenway
No abstract text is available yet for this article.
March 2024: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/38411629/are-mystical-experiences-essential-for-antidepressant-actions-of-ketamine-and-the-classic-psychedelics
#35
REVIEW
Kenji Hashimoto
The growing interest in the rapid and sustained antidepressant effects of the dissociative anesthetic ketamine and classic psychedelics, such as psilocybin, is remarkable. However, both ketamine and psychedelics are known to induce acute mystical experiences; ketamine can cause dissociative symptoms such as out-of-body experience, while psychedelics typically bring about hallucinogenic experiences, like a profound sense of unity with the universe or nature. The role of these mystical experiences in enhancing the antidepressant outcomes for patients with depression is currently an area of ongoing investigation and debate...
February 27, 2024: European Archives of Psychiatry and Clinical Neuroscience
https://read.qxmd.com/read/38402253/hippocampal-volume-changes-after-r-s-ketamine-administration-in-patients-with-major-depressive-disorder-and-healthy-volunteers
#36
JOURNAL ARTICLE
Jennifer W Evans, Morgan C Graves, Allison C Nugent, Carlos A Zarate
The hippocampus and amygdala have been implicated in the pathophysiology and treatment of major depressive disorder (MDD). Preclinical models suggest that stress-related changes in these regions can be reversed by antidepressants, including ketamine. Clinical studies have identified reduced volumes in MDD that are thought to be potentiated by early life stress and worsened by repeated depressive episodes. This study used 3T and 7T structural magnetic resonance imaging data to examine longitudinal changes in hippocampal and amygdalar subfield volumes associated with ketamine treatment...
February 24, 2024: Scientific Reports
https://read.qxmd.com/read/38402231/neurophysiological-evidence-that-frontoparietal-connectivity-and-gaba-a-receptor-changes-underpin-the-antidepressant-response-to-ketamine
#37
JOURNAL ARTICLE
Rachael L Sumner, Rebecca L McMillan, Anna Forsyth, Suresh D Muthukumaraswamy, Alexander D Shaw
Revealing the acute cortical pharmacodynamics of an antidepressant dose of ketamine in humans with depression is key to determining the specific mechanism(s) of action for alleviating symptoms. While the downstream effects are characterised by increases in plasticity and reductions in depressive symptoms-it is the acute response in the brain that triggers this cascade of events. Computational modelling of cortical interlaminar and cortico-cortical connectivity and receptor dynamics provide the opportunity to interrogate this question using human electroencephalography (EEG) data recorded during a ketamine infusion...
February 24, 2024: Translational Psychiatry
https://read.qxmd.com/read/38395521/loss-of-the-sustained-antidepressant-like-effect-of-2r-6r-hydroxynorketamine-in-nmda-receptor-glun2d-subunit-knockout-mice
#38
JOURNAL ARTICLE
Aimi Yamagishi, Yuiko Ikekubo, Masayoshi Mishina, Kazutaka Ikeda, Soichiro Ide
Ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, has attracted attention for its acute and sustained antidepressant effects in patients with depression. Hydroxynorketamine (HNK), a metabolite of ketamine, exerts antidepressant effects without exerting ketamine's side effects and has attracted much attention in recent years. However, the detailed pharmacological mechanism of action of HNK remains unclear. We previously showed that the GluN2D NMDA receptor subunit is important for sustained antidepressant-like effects of (R)-ketamine...
March 2024: Journal of Pharmacological Sciences
https://read.qxmd.com/read/38388704/-r-ketamine-restores-anterior-insular-cortex-activity-and-cognitive-deficits-in-social-isolation-reared-mice
#39
JOURNAL ARTICLE
Rei Yokoyama, Yukio Ago, Hisato Igarashi, Momoko Higuchi, Masato Tanuma, Yuto Shimazaki, Takafumi Kawai, Kaoru Seiriki, Misuzu Hayashida, Shun Yamaguchi, Hirokazu Tanaka, Takanobu Nakazawa, Yasushi Okamura, Kenji Hashimoto, Atsushi Kasai, Hitoshi Hashimoto
Chronic social isolation increases the risk of mental health problems, including cognitive impairments and depression. While subanesthetic ketamine is considered effective for cognitive impairments in patients with depression, the neural mechanisms underlying its effects are not well understood. Here we identified unique activation of the anterior insular cortex (aIC) as a characteristic feature in brain-wide regions of mice reared in social isolation and treated with (R)-ketamine, a ketamine enantiomer. Using fiber photometry recording on freely moving mice, we found that social isolation attenuates aIC neuronal activation upon social contact and that (R)-ketamine, but not (S)-ketamine, is able to counteracts this reduction...
February 23, 2024: Molecular Psychiatry
https://read.qxmd.com/read/38386251/recent-advances-in-the-treatment-of-treatment-resistant-depression-a-narrative-review-of-literature-published-from-2018-to-2023
#40
REVIEW
John L Havlik, Syed Wahid, Kayla M Teopiz, Roger S McIntyre, John H Krystal, Taeho Greg Rhee
PURPOSE OF REVIEW: We review recent advances in the treatment of treatment-resistant depression (TRD), a disorder with very limited treatment options until recently. We examine advances in psychotherapeutic, psychopharmacologic, and interventional psychiatry approaches to treatment of TRD. We also highlight various definitions of TRD in recent scientific literature. RECENT FINDINGS: Recent evidence suggests some forms of psychotherapy can be effective as adjunctive treatments for TRD, but not as monotherapies alone...
February 22, 2024: Current Psychiatry Reports
keyword
keyword
109713
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.